Head-to-head evidence
Abp 234 vs MB12
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Abp 234
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06430866 (registry estimate)
MB12
Developed by Laboratorio Elea Phoenix S.A.
NCT05668650 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · MB12's landscape